PMID- 28869107
OWN - NLM
STAT- MEDLINE
DCOM- 20180801
LR  - 20180801
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 213
IP  - 11
DP  - 2017 Nov
TI  - Molecular characterization of a series of solitary fibrous tumors, including 
      immunohistochemical expression of STAT6 and NATB2-STAT6 fusion transcripts, using 
      Reverse Transcriptase(RT)-Polymerase chain reaction(PCR) technique: An Indian 
      experience.
PG  - 1404-1411
LID - S0344-0338(17)30687-8 [pii]
LID - 10.1016/j.prp.2017.08.011 [doi]
AB  - A solitary fibrous tumor (SFT) is characterized by a diverse clinicopathologic 
      spectrum. Recent studies have unraveled STAT6 as a useful diagnostic 
      immunohistochemical (IHC) marker for a SFT and NAB2-STAT6 as its specific gene 
      fusion transcript. Thirty-three SFTs were tested for STAT6 immunostaining by 
      polymer detection technique. STAT6 immunoexpression was further graded, based on 
      intensity (mild, moderate and strong) and percentage of immunopositive tumor 
      cells, ranging from 1 to 25%(1+); 26-50%(2+); 51-75%(3+) and in more than 75%(4+) 
      tumor nuclei. These cases along with 17 other tumors were tested for 8 variants 
      of NAB2-STAT6, using qualitative endpoint reverse-transcriptase (RT)-PCR 
      technique. RNA extraction was performed using Recover All Total nucleic acid 
      extraction kit. The selected cases were screened for all the 8 fusion variants, 
      using 8 primer pairs for NAB2 and STAT6 genes. Thirty-three SFTs occurred in 18 
      men and 15 women (M: F=1.2:1), with age varying from 13 to 74 
      years(average=49.6); across various body sites. Immunohistochemically, most SFTs 
      (30/33) (90.9%) displayed moderate to strong immunostaining for STAT6, including 
      3+ and 4+ immunostaining patterns in 27/33 (81.8%) tumors. By RT-PCR, 
      30/33(90.9%) cases of SFT were positive for NAB2-STAT6 fusions, including 
      NAB2ex4/STAT6ex2 (7cases), NAB2ex7/STAT6ex2 (7cases), NAB2ex6/STAT6ex3 (6cases), 
      NAB2ex6/SAT6ex16 (4cases), NAB2ex3/STAT6ex19 (4cases), NAB2ex6/STAT6ex17 (single 
      case), NAB2ex4/STAT6ex4 (single case) and NAB2ex6/STAT6ex18 (none). NAB2-STAT6 
      fusions were not observed in 9 cases of synovial sarcoma, 4 of Ewing sarcoma, 2 
      of MPNST and 2 cases of dedifferentiated liposarcomas (100% specificity). On 
      comparing with clinical outcomes, more cases (7/11)(63.6%) of classic SFT were 
      associated with favorable outcomes, while more cases(5/8)(62%) of atypical and 
      malignant SFTs were associated with aggressive outcomes. This study reinforces 
      high sensitivity and specificity of NAB2-STAT6 fusion and its correlation with 
      strong and diffuse IHC expression of STAT6 in a SFT, irrespective of its 
      occurrence in various body sites and its histopathologic types. NAB2ex4-STAT6ex2 
      and NAB2ex7-STAT6ex2 fusions were relatively more frequently observed in our 
      patients. Atypical and malignant SFTs, together, were more frequently associated 
      with relatively aggressive clinical outcomes.
CI  - Copyright (c) 2017 Elsevier GmbH. All rights reserved.
FAU - Rekhi, Bharat
AU  - Rekhi B
AD  - Department of Surgical Pathology, Tata Memorial Centre, Mumbai, Maharashtra, 
      India; Division of Molecular Pathology, Department of Pathology, Tata Memorial 
      Centre, Mumbai, Maharashtra, India. Electronic address: rekhi.bharat@gmail.com.
FAU - Shetty, Omshree
AU  - Shetty O
AD  - Division of Molecular Pathology, Department of Pathology, Tata Memorial Centre, 
      Mumbai, Maharashtra, India.
FAU - Tripathi, Parul
AU  - Tripathi P
AD  - Department of Surgical Pathology, Tata Memorial Centre, Mumbai, Maharashtra, 
      India.
FAU - Bapat, Prachi
AU  - Bapat P
AD  - Division of Molecular Pathology, Department of Pathology, Tata Memorial Centre, 
      Mumbai, Maharashtra, India.
FAU - Ramadwar, Mukta
AU  - Ramadwar M
AD  - Department of Surgical Pathology, Tata Memorial Centre, Mumbai, Maharashtra, 
      India; Division of Molecular Pathology, Department of Pathology, Tata Memorial 
      Centre, Mumbai, Maharashtra, India.
FAU - Bajpai, Jyoti
AU  - Bajpai J
AD  - Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
FAU - Puri, Ajay
AU  - Puri A
AD  - Department of Surgical Oncology (Bone and Soft Tissues), Tata Memorial Centre, 
      Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20170826
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (STAT6 Transcription Factor)
RN  - 0 (STAT6 protein, human)
RN  - EC 2.7.7.49 (RNA-Directed DNA Polymerase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - Female
MH  - Gene Fusion/*genetics
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics
MH  - RNA-Directed DNA Polymerase/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - STAT6 Transcription Factor/*genetics
MH  - Solitary Fibrous Tumors/*genetics/*pathology
MH  - Young Adult
OTO - NOTNLM
OT  - Hemangiopericytoma
OT  - Molecular diagnosis in soft tissue tumors
OT  - NAB2-STAT6
OT  - STAT6
OT  - Solitary fibrous tumor
EDAT- 2017/09/05 06:00
MHDA- 2018/08/02 06:00
CRDT- 2017/09/05 06:00
PHST- 2017/07/04 00:00 [received]
PHST- 2017/07/29 00:00 [revised]
PHST- 2017/08/20 00:00 [accepted]
PHST- 2017/09/05 06:00 [pubmed]
PHST- 2018/08/02 06:00 [medline]
PHST- 2017/09/05 06:00 [entrez]
AID - S0344-0338(17)30687-8 [pii]
AID - 10.1016/j.prp.2017.08.011 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2017 Nov;213(11):1404-1411. doi: 10.1016/j.prp.2017.08.011. 
      Epub 2017 Aug 26.